Medicare Part D Payments for Generic Imatinib From 2017 to 2023.
作者信息
Dusetzina Stacie B
机构信息
Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
出版信息
JAMA Intern Med. 2024 Jan 1;184(1):104-105. doi: 10.1001/jamainternmed.2023.3932.
Abstract
摘要
相似文献
1
Medicare Part D Payments for Generic Imatinib From 2017 to 2023.
JAMA Intern Med. 2024 Jan 1;184(1):104-105. doi: 10.1001/jamainternmed.2023.3932.
2
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
J Clin Oncol. 2023 Oct 10;41(29):4664-4668. doi: 10.1200/JCO.23.00079. Epub 2023 Jun 8.
3
A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
J Manag Care Spec Pharm. 2014 Sep;20(9):959-67. doi: 10.18553/jmcp.2014.20.9.959.
4
Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Ophthalmology. 2018 Mar;125(3):332-339. doi: 10.1016/j.ophtha.2017.05.024. Epub 2017 Jun 16.
5
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
6
Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.
7
Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
Res Social Adm Pharm. 2010 Jun;6(2):121-9. doi: 10.1016/j.sapharm.2010.03.004. Epub 2010 May 7.
8
Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):819-826. doi: 10.1002/pds.4224. Epub 2017 May 9.
9
Examining Opportunities to Increase Savings From Medicare Price Negotiations.
JAMA Intern Med. 2023 Jun 1;183(6):581-588. doi: 10.1001/jamainternmed.2023.0763.
10
The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Am Econ Rev. 2010 Mar;100(1):590-607. doi: 10.1257/aer.100.1.590.
引用本文的文献
1
The high costs of anticancer therapies in the USA: challenges, opportunities and progress.
Nat Rev Clin Oncol. 2024 Dec;21(12):888-899. doi: 10.1038/s41571-024-00948-1. Epub 2024 Oct 4.
Zotero 插件